|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US4752585A
(en)
|
1985-12-17 |
1988-06-21 |
Cetus Corporation |
Oxidation-resistant muteins
|
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
|
US5037644A
(en)
|
1986-10-27 |
1991-08-06 |
Cetus Corporation |
Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
FR2775435B1
(fr)
|
1998-02-27 |
2000-05-26 |
Bioalliance Pharma |
Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
TR200100254T2
(tr)
|
1998-07-13 |
2001-06-21 |
Expression Genetics, Inc. |
Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
WO2003015697A2
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
CA2492807A1
(en)
|
2002-07-29 |
2004-03-04 |
Nanodel Technologies Gmbh |
Nanoparticles for dna administration to a target organ
|
|
PL1628685T3
(pl)
|
2003-04-25 |
2011-05-31 |
Gilead Sciences Inc |
Przeciwwirusowe analogi fosfonianowe
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US7727969B2
(en)
|
2003-06-06 |
2010-06-01 |
Massachusetts Institute Of Technology |
Controlled release nanoparticle having bound oligonucleotide for targeted delivery
|
|
EP1723251A4
(en)
|
2004-03-05 |
2008-04-23 |
Novartis Vaccines & Diagnostic |
IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
|
|
JP4773434B2
(ja)
|
2004-05-19 |
2011-09-14 |
イムノコア リミテッド |
高親和性ｎｙ−ｅｓｏｔ細胞受容体
|
|
EP1778251B1
(en)
|
2004-07-27 |
2011-04-13 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates as anti hiv agents
|
|
WO2006031221A1
(en)
|
2004-09-13 |
2006-03-23 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Compositions comprising t cell receptors and methods of use thereof
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
|
CN101146823A
(zh)
|
2005-02-15 |
2008-03-19 |
阿波罗生命科学有限公司 |
分子及其嵌合分子
|
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
CN101287831B
(zh)
|
2005-09-13 |
2013-05-15 |
国立大学法人三重大学 |
T细胞受体和编码该受体的核酸
|
|
SI2049506T2
(sl)
|
2006-07-07 |
2024-07-31 |
Gilead Sciences, Inc. |
Modulatorji farmakokinetičnih lastnosti terapevtikov
|
|
PT2038290E
(pt)
|
2006-07-07 |
2013-12-10 |
Gilead Sciences Inc |
Moduladores de receptor do tipo toll 7
|
|
SI2170888T1
(sl)
|
2007-06-29 |
2015-10-30 |
Gilead Sciences, Inc. |
Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7
|
|
KR20100065190A
(ko)
|
2007-09-14 |
2010-06-15 |
닛토덴코 가부시키가이샤 |
약물 담체
|
|
WO2009062285A1
(en)
|
2007-11-16 |
2009-05-22 |
Boehringer Ingelheim International Gmbh |
Inhibitors of human immunodeficiency virus replication
|
|
HRP20130048T1
(hr)
|
2008-04-23 |
2013-02-28 |
Gilead Sciences, Inc. |
Karba-nukleozidni analozi za antivirusnu terapiju
|
|
EP2288700B1
(en)
|
2008-05-09 |
2017-02-08 |
Agency for Science, Technology And Research |
Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
|
|
ES2524266T3
(es)
|
2008-07-08 |
2014-12-04 |
Incyte Corporation |
1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
|
|
JP5600104B2
(ja)
|
2008-08-01 |
2014-10-01 |
ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド |
Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
|
|
AU2009333559B2
(en)
|
2008-12-09 |
2015-03-12 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
US8252906B2
(en)
|
2009-01-05 |
2012-08-28 |
Dcb-Usa Llc |
Anti-herpes simplex virus antibodies and methods of use thereof
|
|
CN108530543B
(zh)
|
2009-02-03 |
2023-06-23 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
EP2408819A2
(en)
|
2009-03-20 |
2012-01-25 |
Ludwig Institute for Cancer Research Ltd |
High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof
|
|
FR2945538B1
(fr)
|
2009-05-12 |
2014-12-26 |
Sanofi Aventis |
Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
|
|
US8338441B2
(en)
|
2009-05-15 |
2012-12-25 |
Gilead Sciences, Inc. |
Inhibitors of human immunodeficiency virus replication
|
|
PL2467377T3
(pl)
|
2009-08-18 |
2017-10-31 |
Ventirx Pharmaceuticals Inc |
Podstawione benzoazepiny jako modulatory receptora toll-podobnego
|
|
RU2580320C2
(ru)
|
2009-08-18 |
2016-04-10 |
Вентиркс Фармасьютикалз, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
|
|
JP2013505236A
(ja)
|
2009-09-16 |
2013-02-14 |
デューク ユニバーシティー |
Ｈｉｖ−１抗体
|
|
CA2774636C
(en)
|
2009-09-25 |
2019-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 and their use
|
|
EP2308895A1
(en)
|
2009-10-01 |
2011-04-13 |
Universität Duisburg-Essen |
Anti-HSV antibody
|
|
WO2011046623A2
(en)
|
2009-10-16 |
2011-04-21 |
Duke University |
Hiv-1 antibodies
|
|
MX2012004706A
(es)
|
2009-10-22 |
2012-06-08 |
Gilead Sciences Inc |
Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
|
|
WO2011055888A1
(en)
|
2009-11-06 |
2011-05-12 |
Chung-Ang University Industry-Academy Cooperation Foundtion |
Nanoparticle-based gene delivery systems
|
|
CN102869682B
(zh)
|
2009-11-18 |
2016-10-19 |
曼康公司 |
单克隆抗体及其诊断用途
|
|
SG177025A1
(en)
|
2010-06-21 |
2012-01-30 |
Agency Science Tech & Res |
Hepatitis b virus specific antibody and uses thereof
|
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
EP4450523A3
(en)
|
2010-04-02 |
2025-03-12 |
Amunix Pharmaceuticals, Inc. |
Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
|
|
WO2011139637A1
(en)
|
2010-05-03 |
2011-11-10 |
Philadelphia Health & Education Corporation |
Small-molecule modulators of hiv-1 capsid stability and methods thereof
|
|
MX2012013622A
(es)
|
2010-05-31 |
2013-02-01 |
Ono Pharmaceutical Co |
Derivado de purinona.
|
|
KR101209266B1
(ko)
|
2010-06-30 |
2012-12-06 |
한국과학기술연구원 |
생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
|
|
PH12013500015A1
(en)
|
2010-07-02 |
2013-02-18 |
Gilead Sciences Inc |
2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
|
|
AP2013006706A0
(en)
|
2010-07-02 |
2013-02-28 |
Gilead Sciences Inc |
Napht-2-ylacetic acid derivatives to treat AIDS
|
|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
EP3556396B1
(en)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
RU2016118628A
(ru)
|
2010-10-01 |
2018-11-02 |
Вентиркс Фармасьютикалз, Инк. |
Способы лечения аллергических заболеваний
|
|
CN107970451A
(zh)
|
2010-10-01 |
2018-05-01 |
帆德制药股份有限公司 |
Tlr激动剂和联合治疗的治疗应用
|
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
PY1153144A
(es)
|
2010-12-10 |
2015-01-01 |
Gilead Sciences Inc |
Inhibidores macrocíclicos de virus flaviviridae
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
NZ611439A
(en)
|
2010-12-30 |
2015-05-29 |
Samyang Biopharmaceuticals |
Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
|
|
CA2824779C
(en)
|
2011-01-12 |
2020-01-14 |
Array Biopharma, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
ES2620605T3
(es)
|
2011-01-12 |
2017-06-29 |
Ventirx Pharmaceuticals, Inc. |
Benzoazepinas sustituidas como moduladores de receptores tipo Toll
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
JP5745102B2
(ja)
|
2011-02-12 |
2015-07-08 |
グローブイミューン，インコーポレイテッド |
慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
|
|
KR101946499B1
(ko)
|
2011-04-08 |
2019-02-11 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 치료를 위한 피리미딘 유도체
|
|
CA2832738A1
(en)
|
2011-04-08 |
2012-10-11 |
Duke University |
Herpes simplex virus
|
|
UA111841C2
(uk)
|
2011-04-21 |
2016-06-24 |
Гіліад Сайєнсіз, Інк. |
Сполуки бензотіазолу та їх фармацевтичне застосування
|
|
CN116948019A
(zh)
|
2011-05-17 |
2023-10-27 |
洛克菲勒大学 |
人类免疫缺陷病毒中和抗体及其使用方法
|
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
|
SG194852A1
(en)
|
2011-05-18 |
2013-12-30 |
Janssen R & D Ireland |
Quinazoline derivatives for the treatment of viral infections and further diseases
|
|
EP3626739A1
(en)
|
2011-06-24 |
2020-03-25 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
ES2553449T3
(es)
|
2011-07-06 |
2015-12-09 |
Gilead Sciences, Inc. |
Compuestos para el tratamiento de VIH
|
|
CN102863512B
(zh)
|
2011-07-07 |
2016-04-20 |
上海泓博智源医药技术有限公司 |
抗病毒化合物
|
|
EP2736532B1
(en)
|
2011-07-25 |
2018-05-16 |
California Institute of Technology |
Compositions and methods for improving potency and breadth or hiv antibodies
|
|
US9493549B2
(en)
|
2011-07-25 |
2016-11-15 |
The Rockefeller University |
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
|
|
CA3114877C
(en)
|
2011-09-15 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
|
|
WO2013041865A1
(en)
|
2011-09-22 |
2013-03-28 |
Immunocore Limited |
T cell receptors
|
|
RU2624046C2
(ru)
|
2011-11-07 |
2017-06-30 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
Gp41-нейтрализующие антитела и их применение
|
|
KR101383324B1
(ko)
|
2011-11-10 |
2014-04-28 |
주식회사 종근당 |
신규한 유전자 전달용 조성물
|
|
DK2786996T3
(en)
|
2011-11-29 |
2016-12-19 |
Ono Pharmaceutical Co |
Hydrochloride PURINONDERIVAT
|
|
WO2013091096A1
(en)
|
2011-12-20 |
2013-06-27 |
Boehringer Ingelheim International Gmbh |
Condensed triclyclic compounds as inhibitors of hiv replication
|
|
KR101939710B1
(ko)
|
2011-12-21 |
2019-01-17 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
|
JP6460796B2
(ja)
|
2012-01-17 |
2019-01-30 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
高親和性ｓｉｒｐ−アルファ試薬
|
|
JP6283320B2
(ja)
|
2012-02-08 |
2018-02-21 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
|
|
CA2865578C
(en)
|
2012-02-27 |
2023-01-17 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2013144129A1
(en)
|
2012-03-31 |
2013-10-03 |
F. Hoffmann-La Roche Ag |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
US9096586B2
(en)
|
2012-04-20 |
2015-08-04 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
WO2013185103A1
(en)
|
2012-06-08 |
2013-12-12 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of flaviviridae viruses
|
|
WO2013185090A1
(en)
|
2012-06-08 |
2013-12-12 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of flaviviridae viruses
|
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
|
WO2013192589A1
(en)
|
2012-06-21 |
2013-12-27 |
California Institute Of Technology |
Antibodies targeting hiv escape mutants
|
|
US9771427B2
(en)
|
2012-08-09 |
2017-09-26 |
Roche Glycart Ag |
ASGPR antibodies and uses thereof
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
MX369417B
(es)
|
2012-08-10 |
2019-11-07 |
Janssen Sciences Ireland Uc |
Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades.
|
|
EP2882706A1
(en)
|
2012-08-13 |
2015-06-17 |
Massachusetts Institute of Technology |
Amine-containing lipidoids and uses thereof
|
|
CN104797561B
(zh)
|
2012-08-28 |
2017-03-01 |
爱尔兰詹森科学公司 |
稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途
|
|
UY34993A
(es)
|
2012-08-28 |
2014-02-28 |
Janssen R & D Ireland |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
|
|
MX2015002954A
(es)
|
2012-09-10 |
2015-06-05 |
Hoffmann La Roche |
Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
|
|
BR112015007083A2
(pt)
|
2012-10-02 |
2017-07-04 |
Epitherapeutics Aps |
inibidores de histona demetilases
|
|
EA035327B1
(ru)
|
2012-10-10 |
2020-05-28 |
Янссен Сайенсиз Айрлэнд Юси |
Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
|
|
EA035012B1
(ru)
|
2012-10-18 |
2020-04-17 |
Рокфеллер Юниверсити (Дзе) |
Нейтрализующие анти-вич-антитела широкого спектра действия
|
|
KR101268466B1
(ko)
|
2012-11-12 |
2013-06-04 |
유병수 |
사축형 윈드 터빈
|
|
ES2655843T3
(es)
|
2012-11-16 |
2018-02-21 |
Janssen Sciences Ireland Uc |
Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas
|
|
WO2014089364A1
(en)
|
2012-12-06 |
2014-06-12 |
Quanticel Pharmaceuticals, Inc |
Histone demethylase inhibitors
|
|
HRP20192013T1
(hr)
|
2012-12-17 |
2020-02-07 |
Trillium Therapeutics Inc. |
Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
|
|
HUE037312T2
(hu)
|
2012-12-19 |
2018-08-28 |
Celgene Quanticel Res Inc |
Hiszton demetiláz inhibitorok
|
|
CA2895808A1
(en)
|
2012-12-21 |
2014-06-26 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
|
CA2893843C
(en)
|
2012-12-21 |
2018-09-04 |
Gilead Sciences, Inc. |
Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
|
|
HK1214817A1
(en)
|
2012-12-27 |
2016-08-05 |
Japan Tobacco Inc. |
Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
|
|
HUE050390T2
(hu)
|
2013-01-29 |
2020-11-30 |
Max Delbrueck Centrum Fuer Molekulare Medizin Mdc |
MAGE-A 1-t felismerõ nagy aviditású kötõ molekulák
|
|
MY191389A
(en)
|
2013-02-21 |
2022-06-22 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
|
WO2014131847A1
(en)
|
2013-02-28 |
2014-09-04 |
Janssen R&D Ireland |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
TWI694071B
(zh)
|
2013-03-01 |
2020-05-21 |
美商基利科學股份有限公司 |
治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
|
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
|
US9738637B2
(en)
|
2013-03-12 |
2017-08-22 |
Celgene Quantical Research, Inc. |
Histone demethylase inhibitors
|
|
RU2015143517A
(ru)
|
2013-03-13 |
2017-04-19 |
Дженентек, Инк. |
Пиразолсодержащие соединения и их применения
|
|
US9133166B2
(en)
|
2013-03-14 |
2015-09-15 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
|
RS56561B1
(sr)
|
2013-03-15 |
2018-02-28 |
Quanticel Pharmaceuticals Inc |
Inhibitori histon demetilaze
|
|
JP6419155B2
(ja)
|
2013-04-03 |
2018-11-07 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
|
|
JO3583B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
HRP20181863T1
(hr)
|
2013-05-17 |
2018-12-28 |
Janssen Sciences Ireland Uc |
Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
|
|
EA201592126A1
(ru)
|
2013-05-17 |
2016-05-31 |
Ф. Хоффманн-Ля Рош Аг |
6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
|
|
NO3024819T3
(pl)
|
2013-07-25 |
2018-07-21 |
|
|
|
GB201313377D0
(en)
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
|
PL3043865T3
(pl)
|
2013-09-11 |
2021-07-05 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
SPOSOBY I KOMPOZYCjE FARMACEUTYCZNE W LECZENIU ZAKAŻENIA WIRUSEM ZAPALENIA WĄTROBY TYPU B
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
HK1223094A1
(zh)
|
2013-11-14 |
2017-07-21 |
Novira Therapeutics Inc. |
氮杂环庚烷衍生物和治疗乙型肝炎感染的方法
|
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JP2017504633A
(ja)
|
2014-01-30 |
2017-02-09 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防のための新規なジヒドロキノリジノン
|
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
|
ES2714110T3
(es)
|
2014-03-07 |
2019-05-27 |
Hoffmann La Roche |
Heteroarildihidropirimidinas 6-fusionadas novedosas para el tratamiento y profilaxis de la infección por el virus de la hepatitis B
|
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
|
CA2948080A1
(en)
|
2014-05-13 |
2015-11-19 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
|
RU2016149812A
(ru)
|
2014-06-06 |
2018-07-17 |
Флексус Байосайенсиз, Инк. |
Иммунорегулирующие средства
|
|
NO2717902T3
(pl)
|
2014-06-20 |
2018-06-23 |
|
|
|
ES2843277T3
(es)
|
2014-06-26 |
2021-07-16 |
Heidelberg Immunotherapeutics Gmbh |
Aplicación tópica para un anticuerpo anti-VHS
|
|
WO2016012470A1
(en)
|
2014-07-25 |
2016-01-28 |
F. Hoffmann-La Roche Ag |
New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
|
|
ES2962260T3
(es)
|
2014-08-08 |
2024-03-18 |
Univ Leland Stanford Junior |
Proteínas de fusión SIRPa alfa-anticuerpo
|
|
CN106573898B
(zh)
|
2014-08-14 |
2018-11-09 |
豪夫迈·罗氏有限公司 |
治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮
|
|
EA201790154A1
(ru)
|
2014-08-27 |
2017-08-31 |
Джилид Сайэнс, Инк. |
Соединения и способы для ингибирования гистоновых деметилаз
|
|
KR20230156963A
(ko)
|
2014-10-07 |
2023-11-15 |
엠와이알 게엠베하 |
Hbv 및 hdv 감염의 조합 치료법
|
|
GB201417803D0
(en)
|
2014-10-08 |
2014-11-19 |
Adaptimmune Ltd |
T cell receptors
|
|
WO2016057924A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
|
MX2017006016A
(es)
|
2014-11-11 |
2017-06-19 |
Amunix Operating Inc |
Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
|
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
|
AR103222A1
(es)
|
2014-12-23 |
2017-04-26 |
Hoffmann La Roche |
Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
|
|
US9527845B2
(en)
|
2014-12-30 |
2016-12-27 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis B infections
|
|
CN107108610B
(zh)
|
2014-12-30 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
|
|
CN107109497A
(zh)
|
2014-12-31 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
|
|
MA41338B1
(fr)
|
2015-01-16 |
2019-07-31 |
Hoffmann La Roche |
Composés de pyrazine pour le traitement de maladies infectieuses
|
|
WO2016120186A1
(en)
|
2015-01-27 |
2016-08-04 |
F. Hoffmann-La Roche Ag |
Recombinant hbv cccdna, the method to generate thereof and the use thereof
|
|
AU2015380301B2
(en)
|
2015-01-28 |
2020-04-23 |
Dnx Biotech, Llc |
Compositions and methods of using a soluble TNF-alpha receptor modified for increased half-life
|
|
EP3050897A1
(en)
|
2015-01-28 |
2016-08-03 |
Polichem S.A. |
Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2
|
|
WO2016130451A1
(en)
|
2015-02-09 |
2016-08-18 |
Dnx Biotech, Llc |
Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody
|
|
EP3256471B1
(en)
|
2015-02-11 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2016142783A2
(en)
|
2015-03-10 |
2016-09-15 |
Leiden University Medical Center |
T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
|
|
WO2016149698A2
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
|
|
US10442788B2
(en)
|
2015-04-01 |
2019-10-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US10273228B2
(en)
|
2015-04-17 |
2019-04-30 |
Indiana University Research And Technology Corporation |
Hepatitis B viral assembly effectors
|
|
EP3292120B1
(en)
|
2015-05-04 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
CN106188275A
(zh)
|
2015-05-06 |
2016-12-07 |
广州市香雪制药股份有限公司 |
识别ny-eso-1抗原短肽的t细胞受体
|
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
CN107921127B
(zh)
|
2015-05-22 |
2022-04-08 |
纪念斯隆-凯特琳癌症中心 |
对于prame肽具有特异性的t细胞受体样抗体
|
|
US10196701B2
(en)
|
2015-06-01 |
2019-02-05 |
The Penn State Research Foundation |
Hepatitis B virus capsid assembly
|
|
KR20180012850A
(ko)
|
2015-06-24 |
2018-02-06 |
유레카 쎄라퓨틱스, 인코포레이티드 |
Ny-eso-1 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
|
|
GB201511477D0
(en)
|
2015-06-30 |
2015-08-12 |
Redx Pharma Plc |
Antiviral compounds
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2017007701A1
(en)
|
2015-07-07 |
2017-01-12 |
Merck Sharp & Dohme Corp. |
Antiviral phosphodiamide compounds
|
|
CN107849037B
(zh)
|
2015-07-21 |
2020-04-17 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
|
|
WO2017016960A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
|
|
WO2017017042A1
(en)
|
2015-07-27 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
JP6559324B2
(ja)
|
2015-07-28 |
2019-08-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
|
|
TWI639598B
(zh)
|
2015-08-10 |
2018-11-01 |
美商默沙東藥廠 |
抗病毒β－胺基酸酯磷酸二醯胺化合物
|
|
CA2997749A1
(en)
|
2015-09-09 |
2017-03-16 |
Immune Design Corp. |
Ny-eso-1 specific tcrs and methods of use thereof
|
|
JP2018527366A
(ja)
|
2015-09-15 |
2018-09-20 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
|
|
TWI721016B
(zh)
|
2015-09-15 |
2021-03-11 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
EP3360554B1
(en)
|
2015-10-05 |
2021-07-28 |
FUJIFILM Toyama Chemical Co., Ltd. |
Anti-hepatitis b virus agent
|
|
WO2017059878A1
(en)
|
2015-10-07 |
2017-04-13 |
Humabs Biomed Sa |
Antibodies that potently neutralize hepatitis b virus and uses thereof
|
|
CA3003878A1
(en)
|
2015-11-03 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 gp41 and their use
|
|
WO2017076308A1
(zh)
|
2015-11-04 |
2017-05-11 |
广州市香雪制药股份有限公司 |
识别ny-eso-1抗原短肽的tcr
|
|
SG10201912984WA
(en)
|
2015-12-02 |
2020-03-30 |
Agenus Inc |
Antibodies and methods of use thereof
|
|
WO2017096276A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
EP3383914A4
(en)
|
2015-12-02 |
2019-10-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
|
|
CA3007022A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
CA3006963A1
(en)
|
2015-12-03 |
2017-06-08 |
Ludwig Institute For Cancer Research Ltd. |
Anti-ox40 antibodies and methods of use thereof
|
|
US10745428B2
(en)
|
2015-12-10 |
2020-08-18 |
Idenix Pharmaceuticals Llc |
Antiviral phosphodiamide prodrugs of tenofovir
|
|
PL3390441T3
(pl)
|
2015-12-15 |
2022-01-10 |
Gilead Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności
|
|
EP3181146A1
(en)
|
2015-12-16 |
2017-06-21 |
Ruprecht-Karls-Universität Heidelberg |
Cyclic ntcp-targeting peptides and their uses as entry inhibitors
|
|
GB201522592D0
(en)
|
2015-12-22 |
2016-02-03 |
Immunocore Ltd |
T cell receptors
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
ES2897913T3
(es)
|
2016-02-19 |
2022-03-03 |
Novartis Ag |
Compuestos de piridona tetracíclicos como antivirales
|
|
KR20190059874A
(ko)
|
2016-04-08 |
2019-05-31 |
어댑티뮨 리미티드 |
T 세포 수용체
|
|
MA44608B1
(fr)
|
2016-04-08 |
2022-06-30 |
Immunocore Ltd |
Récepteurs des lymphocytes t
|
|
RU2018138837A
(ru)
|
2016-04-08 |
2020-05-12 |
Адаптимьюн Лимитед |
Т-клеточные рецепторы
|
|
KR102523449B1
(ko)
|
2016-04-08 |
2023-04-19 |
어댑티뮨 리미티드 |
T 세포 수용체
|
|
CN105925537B
(zh)
|
2016-04-21 |
2019-09-06 |
中国科学院武汉病毒研究所 |
一种抗HSV的糖蛋白gD的单克隆抗体以及产生该抗体的杂交瘤细胞
|
|
US11352410B2
(en)
|
2016-04-26 |
2022-06-07 |
The United States of American, as represented by the Secretary, Department of Health and Human Service |
Anti-KK-LC-1 T cell receptors
|
|
WO2017197048A1
(en)
|
2016-05-11 |
2017-11-16 |
Amunix Operating Inc. |
Albumin binding conjugate compositions and methods of making and using same
|
|
EP3458455B1
(en)
|
2016-05-20 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
|
|
WO2017202798A1
(en)
|
2016-05-26 |
2017-11-30 |
F. Hoffmann-La Roche Ag |
Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
|
|
WO2017211791A1
(en)
|
2016-06-07 |
2017-12-14 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a tlr7 agonist
|
|
SG11201810834WA
(en)
|
2016-06-10 |
2018-12-28 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
CA3029566A1
(en)
|
2016-06-29 |
2018-01-04 |
Novira Therapeutics, Inc. |
Diazepinone derivatives and their use in the treatment of hepatitis b infections
|
|
AU2017286890B2
(en)
|
2016-06-29 |
2021-09-09 |
Novira Therapeutics, Inc. |
Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections
|
|
WO2018001944A1
(en)
|
2016-06-29 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2018001952A1
(en)
|
2016-06-29 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
|
|
JP7051804B2
(ja)
|
2016-07-14 |
2022-04-11 |
エフ．ホフマン－ラ ロシュ アーゲー |
感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物
|
|
WO2018011160A1
(en)
|
2016-07-14 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
|
EP3484885B1
(en)
|
2016-07-14 |
2020-03-04 |
H. Hoffnabb-La Roche Ag |
Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
|
EP3484883B1
(en)
|
2016-07-14 |
2020-04-15 |
H. Hoffnabb-La Roche Ag |
Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases
|
|
CN109563156A
(zh)
|
2016-07-26 |
2019-04-02 |
波利化学公司 |
抗体和抗病毒剂的抗hsv协同活性
|
|
WO2018019297A1
(zh)
|
2016-07-29 |
2018-02-01 |
银杏树药业(苏州)有限公司 |
异喹啉酮类化合物及其制备抗病毒药物的应用
|
|
EP3490987B1
(en)
|
2016-07-29 |
2022-09-21 |
Guangzhou Lupeng Pharmaceutical Company Ltd. |
Novel therapeutic agents for the treatment of hbv infection
|
|
TW202138365A
(zh)
|
2016-08-19 |
2021-10-16 |
美商基利科學股份有限公司 |
治療性化合物
|
|
JP2019526562A
(ja)
|
2016-08-24 |
2019-09-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｈｂｖキャプシドアセンブリ阻害剤とヌクレオシ（チ）ド類似体の併用療法
|
|
WO2018043747A1
(ja)
|
2016-09-05 |
2018-03-08 |
国立大学法人京都大学 |
抗ｂ型肝炎ウイルス剤
|
|
WO2018045911A1
(zh)
|
2016-09-09 |
2018-03-15 |
浙江海正药业股份有限公司 |
二氢嘧啶类化合物及其制备方法和用途
|
|
KR20190052708A
(ko)
|
2016-09-23 |
2019-05-16 |
라이언 티씨알 피티이. 리미티드 |
Hbv 항원 특이적 결합 분자 및 그의 단편
|
|
FI3526323T3
(fi)
|
2016-10-14 |
2023-06-06 |
Prec Biosciences Inc |
Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
|
|
WO2018075564A1
(en)
|
2016-10-17 |
2018-04-26 |
University Of Maryland, College Park |
Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
|
|
WO2018080903A1
(en)
|
2016-10-26 |
2018-05-03 |
Merck Sharp & Dohme Corp. |
Antiviral aryl-amide phosphodiamide compounds
|
|
CN106496331B
(zh)
*
|
2016-11-08 |
2020-03-13 |
北京智岭生物医药科技有限公司 |
一种FSH-Fc融合蛋白及其制备方法和用途
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
WO2018097951A1
(en)
|
2016-11-22 |
2018-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3/a6 antibodies
|
|
MA47131A
(fr)
|
2016-12-22 |
2021-05-12 |
Idenix Pharmaceuticals Llc |
Composés benzyl-amide phosphodiamide antiviraux
|
|
KR20190100250A
(ko)
|
2016-12-22 |
2019-08-28 |
머크 샤프 앤드 돔 코포레이션 |
테노포비르의 항바이러스 지방족 에스테르 전구약물
|
|
KR102760578B1
(ko)
|
2016-12-22 |
2025-02-03 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
JP7041898B2
(ja)
|
2016-12-27 |
2022-03-25 |
ザ ロックフェラー ユニバーシティー |
広域中和抗ｈｉｖ－１抗体およびその使用方法
|
|
AU2018207172B2
(en)
|
2017-01-13 |
2023-10-12 |
Mink Therapeutics, Inc. |
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
AR110922A1
(es)
|
2017-02-06 |
2019-05-15 |
Gilead Sciences Inc |
Compuestos inhibidores del vih
|
|
EP3595708A4
(en)
|
2017-03-15 |
2020-12-16 |
Fred Hutchinson Cancer Research Center |
HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
|
|
DE102017106305A1
(de)
|
2017-03-23 |
2018-09-27 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
WO2018225732A1
(ja)
|
2017-06-05 |
2018-12-13 |
国立大学法人三重大学 |
Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質
|
|
JP7433051B2
(ja)
|
2017-06-19 |
2024-02-19 |
メディシナ セラピューティクス インコーポレイテッド |
Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
|
|
GB201709866D0
(en)
|
2017-06-20 |
2017-08-02 |
Immunocore Ltd |
T cell receptors
|
|
TWI728250B
(zh)
|
2017-06-21 |
2021-05-21 |
美商基利科學股份有限公司 |
靶向hiv gp120及cd3之多特異性抗體
|
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
|
CN111148832A
(zh)
|
2017-08-30 |
2020-05-12 |
Km生物医薬股份公司 |
抗HSV gB单克隆抗体或其抗原结合片段
|
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
|
WO2019084538A1
(en)
|
2017-10-27 |
2019-05-02 |
Board Of Regents, The University Of Texas System |
TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF
|
|
US11274102B2
(en)
|
2017-10-30 |
2022-03-15 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in HIV therapy
|
|
WO2019091384A1
(en)
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
CN109879957B
(zh)
|
2017-12-06 |
2022-03-18 |
香雪生命科学技术（广东）有限公司 |
针对prame的高亲和力t细胞受体
|
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
WO2019129053A1
(zh)
*
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
EP4424710A3
(en)
|
2018-02-26 |
2025-01-15 |
Medigene Immunotherapies GmbH |
Nyeso tcr
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
JP7469807B2
(ja)
|
2018-04-19 |
2024-04-17 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
|
|
CU24554B1
(es)
|
2018-05-07 |
2021-11-04 |
Ct Inmunologia Molecular |
Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
|
|
WO2019226829A1
(en)
|
2018-05-22 |
2019-11-28 |
Beth Israel Deaconess Medical Center, Inc. |
Antibody therapies for human immunodeficiency virus (hiv)
|
|
EP3830108A4
(en)
|
2018-07-27 |
2022-08-10 |
International AIDS Vaccine Initiative |
GENETIC ANTIBODIES AGAINST HIV-ENV
|
|
TWI829205B
(zh)
|
2018-07-30 |
2024-01-11 |
美商基利科學股份有限公司 |
抗hiv化合物
|
|
US12098185B2
(en)
|
2018-08-28 |
2024-09-24 |
Pontificia Universidad Catolica De Chile |
Monoclonal antibody 11B2C7 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
|
|
US12247066B2
(en)
|
2018-08-28 |
2025-03-11 |
Pontificia Universídad Católica de Chile |
Monoclonal antibody 14F5F6 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2
|
|
CN113272435B
(zh)
|
2018-09-05 |
2025-11-14 |
加利福尼亚大学董事会 |
在多个主要组织相容性复合体分子上受限的ny-eso-1特异性t细胞受体的组合物
|
|
CN121021680A
(zh)
|
2018-09-14 |
2025-11-28 |
洛克菲勒大学 |
抗hiv抗体10-1074变体
|
|
PL3715367T3
(pl)
|
2018-09-17 |
2024-09-02 |
Gi Innovation, Inc. |
Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanie
|
|
US12269855B2
(en)
|
2018-09-21 |
2025-04-08 |
Innovent Biologics (Suzhou) Co., Ltd. |
Interleukin-2 and use thereof
|
|
CN110950949B
(zh)
|
2018-09-26 |
2022-04-05 |
香雪生命科学技术（广东）有限公司 |
一种识别ssx2抗原的t细胞受体
|
|
EP3870222A4
(en)
|
2018-10-22 |
2022-07-27 |
International AIDS Vaccine Initiative |
ANTI-HIV ANTIBODIES
|
|
EA202191107A1
(ru)
|
2018-10-23 |
2021-09-17 |
Ридженерон Фармасьютикалз, Инк. |
T-клеточные рецепторы ny-eso-1 и способы их применения
|
|
WO2020092990A1
(en)
|
2018-11-02 |
2020-05-07 |
Eastern Virginia Medical School |
Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery
|
|
WO2020154032A1
(en)
*
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
|
US20200246467A1
(en)
*
|
2019-02-06 |
2020-08-06 |
Synthorx, Inc. |
Il-2 conjugates and methods of use thereof
|
|
CN113874400B
(zh)
*
|
2019-03-11 |
2025-02-07 |
詹森生物科技公司 |
抗Vβ17/抗CD123双特异性抗体
|
|
CU24712B1
(es)
|
2019-03-15 |
2024-07-10 |
Centre Hospitalier Univ Vaudois |
Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
|
|
CR20210500A
(es)
*
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
CA3142738A1
(en)
|
2019-06-05 |
2020-12-10 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
|
|
US20220235109A1
(en)
|
2019-06-14 |
2022-07-28 |
Cugene Inc |
Novel interleukin-2 variants for the treatment of cancer
|
|
KR20220035122A
(ko)
|
2019-06-14 |
2022-03-21 |
큐진 인크. |
신규한 인터루킨-2 변이체 및 이의 이작용성 융합 분자
|
|
EP4122951A4
(en)
|
2020-03-19 |
2024-05-29 |
Innovent Biologics (Singapore) Pte. Ltd. |
INTERLEUKIN-2 MUTANT AND ITS USE
|
|
JP2023518434A
(ja)
|
2020-03-19 |
2023-05-01 |
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド |
インターロイキン２変異体およびその使用
|
|
IL295826B2
(en)
|
2020-03-31 |
2025-11-01 |
Hanmi Pharmaceutical Co Ltd |
Novel immunostimulating il-2 analogs
|
|
EP4185605A4
(en)
|
2020-07-09 |
2024-07-17 |
Eutilex Co., Ltd. |
IL-2 VARIANTS
|
|
CN116113428A
(zh)
|
2020-09-01 |
2023-05-12 |
武田药品工业株式会社 |
白细胞介素-2突变蛋白及其用途
|
|
CN117500518A
(zh)
|
2020-09-18 |
2024-02-02 |
地方独立行政法人 宫城县立医院机构 |
Il-2突变蛋白及包含其的药物
|
|
CN114437228B
(zh)
|
2020-10-30 |
2024-02-06 |
中国科学院生物物理研究所 |
一种il-2与抗体亚单位构成的双功能融合蛋白
|
|
AU2021393752A1
(en)
|
2020-12-04 |
2023-05-18 |
F. Hoffmann-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
|
EP4323392A4
(en)
|
2021-04-16 |
2025-03-19 |
Orionis Biosciences, Inc. |
IL-2-BASED CONSTRUCTS
|